Floatz logo

Arimidex

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

PfizerPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Pfizer
Phase 1/2CCC
Letrozole
Pfizer
Phase 1/2CCC
EXEMESTANE
Pfizer
Phase 1/2CCC
pf-06873600
Pfizer
Phase 1/2CCC

Same molecule, other indications

Arimidex is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative ·
73 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →